TY - JOUR
T1 - Targeting the epidermal growth factor receptor in the treatment of colorectal cancer
T2 - State of the art
AU - Diasio, Robert B.
AU - Fourie, Jeanne
PY - 2006
Y1 - 2006
N2 - The epidermal growth factor receptor (EGFR) is an important mediator of normal cellular processes such as growth, survival, differentiation and morphogenesis. Disturbances in the EGFR pathway have been associated with the development and progression of malignancy, including cellular proliferation, angiogenesis, invasion/metastasis and anti-apoptosis, as well as with resistance to chemotherapy and/or radiation therapy. As a result, this is an excellent rationale for treatment with EGFR-specific therapeutic agents. These agents may be EGFR-targeted antibodies or small molecules that inactivate the receptor tyrosine kinase. While only cetuximab has received US FDA approval for the treatment of colorectal cancer, numerous agents are currently in development and in clinical trials and constitute an area of intensive, ongoing research.
AB - The epidermal growth factor receptor (EGFR) is an important mediator of normal cellular processes such as growth, survival, differentiation and morphogenesis. Disturbances in the EGFR pathway have been associated with the development and progression of malignancy, including cellular proliferation, angiogenesis, invasion/metastasis and anti-apoptosis, as well as with resistance to chemotherapy and/or radiation therapy. As a result, this is an excellent rationale for treatment with EGFR-specific therapeutic agents. These agents may be EGFR-targeted antibodies or small molecules that inactivate the receptor tyrosine kinase. While only cetuximab has received US FDA approval for the treatment of colorectal cancer, numerous agents are currently in development and in clinical trials and constitute an area of intensive, ongoing research.
UR - http://www.scopus.com/inward/record.url?scp=33747340480&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33747340480&partnerID=8YFLogxK
U2 - 10.2165/00003495-200666110-00003
DO - 10.2165/00003495-200666110-00003
M3 - Review article
C2 - 16906777
AN - SCOPUS:33747340480
SN - 0012-6667
VL - 66
SP - 1441
EP - 1463
JO - Drugs
JF - Drugs
IS - 11
ER -